COMP <GO>
XTNT vs JNJ // GROSS PROFIT MARGIN
Xtant Medical Holdings Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: XTNT 4
— JNJ 7
▲ GROSS PROFIT MARGIN LEADER: JNJ
LAST: $0.29 (+1.54%) • MKT CAP: $40.7M
gross-margins
62.90%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XTNT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XTNT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 62.90% | 67.90% | -5.00 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | 25.50% | -12.70 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.7x | 18.5x | -14.80 | XTNT | /valuation <GO> |
| Free Cash Flow Yield | 24.95% | 2.97% | +21.98 | XTNT | /fcf-yield <GO> |
| Operating Margin | 5.40% | 34.70% | -29.30 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.50% | -28.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 14.20% | 6.00% | +8.20 | XTNT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.59 | -5.39 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | XTNT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.9 | 62.1 | -27.16 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.7M | $662.49B | -$662.45B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XTNT REV | JNJ REV | XTNT GROSS % | JNJ GROSS % | XTNT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $133.9M | $94.19B | 62.9% | 67.9% | $10.2M | $19.70B |
| FY 2024 | $117.3M | $88.82B | 58.2% | 69.1% | -$16.0M | $19.84B |
| FY 2023 | $91.3M | $85.16B | — | — | -$9.5M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XTNT // BETA —
JNJ // BETA 1.08